$MGNX News

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors

MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate

MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks